Compare · OM vs TMDX
OM vs TMDX
Side-by-side comparison of Outset Medical Inc. (OM) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OM and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.40B, about 28.3x OM ($84.9M).
- OM has been more active in the news (16 items in the past 4 weeks vs 12 for TMDX).
- TMDX has more recent analyst coverage (18 ratings vs 13 for OM).
- Company
- Outset Medical Inc.
- TransMedics Group Inc.
- Price
- $4.58-3.38%
- $69.37-2.62%
- Market cap
- $84.9M
- $2.40B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 16
- 12
- Recent ratings
- 13
- 18
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest OM
- Director Hackett Patrick T was granted 10,667 shares, increasing direct ownership by 11% to 105,839 units (SEC Form 4)
- Director Oboyle Kevin C was granted 10,667 shares, increasing direct ownership by 44% to 34,785 units (SEC Form 4)
- Director Prange Karen was granted 10,667 shares, increasing direct ownership by 57% to 29,334 units (SEC Form 4)
- Director Lang Brent D. was granted 10,667 shares, increasing direct ownership by 60% to 28,518 units (SEC Form 4)
- Director Grossman D Keith was granted 10,667 shares, increasing direct ownership by 77% to 24,585 units (SEC Form 4)
- Director Drexler Karen was granted 10,667 shares, increasing direct ownership by 100% to 21,317 units (SEC Form 4)
- Chief Financial Officer Gaeta Renee sold $87,300 worth of shares (17,672 units at $4.94), decreasing direct ownership by 13% to 113,753 units (SEC Form 4) (for withholding tax)
- Outset Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Outset Medical Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SD filed by Outset Medical Inc.
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.